FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO), will expand its finished goods autoinjector services through a non-exclusive strategic partnership agreement with SHL Medical (SHL), a provider of advanced drug delivery systems.

The strategic partnership will allow SHL to recommend FUJIFILM Diosynth Biotechnologies for final assembly of the Molly autoinjector to customers seeking CDMO services.

The collaboration, part of SHL’s Alliance Management Program, aims to streamline processes and enhance efficiency for pharmaceutical and biotech companies offering self-injection device finished goods services primarily with SHL’s flagship platform Molly. FUJIFILM Diosynth Biotechnologies will offer pre-validated final assembly services for Molly autoinjectors for its global customers with increased capacity of up to 30 million units per year beginning early 2025.

“Partnering with SHL will expand FUJIFILM Diosynth Biotechnologies’ ability to offer top-quality, high-speed final assembly of autoinjectors to customers seeking our CDMO services,” said Kenneth Bilenberg, chief operating officer, and executive vice president, large-scale business unit, FUJIFILM Diosynth Biotechnologies. “Having access to SHL’s full network of solutions and services will enhance our ability to support our customers in improving patient access using autoinjector medicines.” 

SHL medical chief growth officer Markus Puusepp said, “A number of customers with manufacturing infrastructure in Europe have sought our guidance in recommending a trusted final assembly partner that can support their commitment to a localized supply chain,” said. “It is with great pleasure that we will now be able to recommend FUJIFILM Diosynth Biotechnologies to them with the full confidence that the collaboration will further support their needs for faster timelines to clinic and to market.”